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Abstract
Background: In schizophrenia, genetic background may provide a substrate for intrinsic maldevelopment of the
brain through environmental influences, by recruiting neurotrophic factors and cytokines, to trigger the changes
that lead to impaired neuronal functions. Cytokines being the key regulators of immune/inflammatory reactions are
also known to influence the dopaminergic, noradrenergic, and serotonergic neurotransmission. Therefore, functional
polymorphisms in cytokine genes may result in imbalances in the pro- and anti-inflammatory cytokine production.
Methods: We screened polymorphisms in pro- and anti-inflammatory cytokine genes using a case-control association
study in a South Indian population. The role of allele, genotype, haplotype, and diplotypes of these cytokine genes and
their epistatic interactions were assessed in contributing to the risk of developing schizophrenia. Meta-analysis for the
reported associations was also monitored for global significance.
Results: The pro-inflammatory cytokine gene polymorphisms in IL1Ars1800587, IL6rs1800796, TNFArs361525, and
IFNGrs2069718 were associated with schizophrenia. The study also provides significant evidence for strong epistatic
interactions among pro-inflammatory cytokine genes IL6 and IFNG in the development of schizophrenia. In silico analysis
suggested that associated risk variants were indicative of altered transcriptional activity with higher production of IL1α,
IL-6, TNF-α, and IFN-ɤ cytokines. Meta-analysis indicated heterogeneity among study population while IL1Ars1800587 was
found to be globally significant.
Conclusions: It is important to identify the nature of inflammatory response that can be amplified by the environment,
to influence either Th1 response or Th2 response. The associated functional variants in the study are involved
with increased expression resulting in higher production of the pro-inflammatory cytokines IL-1α, IL-6, TNF-α, and
IFN-γ. The interaction of immunological stressors with these high producer alleles of pro-inflammatory cytokines
may suggest that even a lower threshold may be sufficient to induce a resultant chronic effect on the psycho-social
and environmental stressors that may result in the development and pathogenesis of schizophrenia. Understanding
environmental factors that influence the expression of these pro-inflammatory cytokine genes or their interaction can
possibly help in dissecting the phenotypic variation and therapeutic response to antipsychotics in schizophrenia.
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Background
Schizophrenia is a severe and debilitating mental illness,
affecting about seven to eight individuals per 1000 of the
general population [1]. It is characterized by three broad
spectrum behavioral domains such as positive symptoms
noted as delusions and hallucinations and negative symp-
toms noted as apathy, anhedonia, social withdrawal, and
cognitive domain [2]. These behavioral domains tend to
vary in their presentation based on ethnicity, culture, or
environmental conditions which might impact treatment
and its outcome [3]. These facts make schizophrenia a
complex disorder which involves multiple genes with mild
to moderate effect and non-genetic risk factors like envir-
onmental and psychological assaults that alter the brain’s
chemistry [4]. Numerous theories have been proposed
regarding the cause of schizophrenia, ranging from de-
velopmental or neurodegenerative processes or neuro-
transmitter abnormalities to infectious or autoimmune
processes. A number of environmental factors have been
implicated for increased risk to schizophrenia, such as ma-
ternal infections [5], obstetric complications [6], neonatal
hypoxia, and brain injury [7]. Besides these, schizophrenia
patients experience elevated morbidity from infectious
and autoimmune diseases [8]. These environmental risk
factors recruit cytokines to the brain to mediate inflamma-
tory processes [9]. Thus, cytokines being the key regulator
of immune/inflammatory reactions and brain develop-
ment emerge as a common pathway for genetic and envir-
onmental components of schizophrenia.
Cytokines can act as signals between cells to regulate the
immune response to injury and infections [10]. Besides pro-
viding communication between immune cells, they also
play a role in signaling the brain to produce neurochemical,
neuroendocrine, neuroimmune, and behavioral changes
[10]. Cytokines can strongly influence the dopaminergic,
noradrenergic, and serotonergic neurotransmission [11].
Pathogenic nature of neurotransmission can be mediated
by alterations in the equilibrium status of Th1/Th2 re-
sponse resulting in schizophrenia. Elevated levels of cer-
tain cytokines have been reported both in the serum and
cerebrospinal fluid (CSF) of patients with schizophrenia
[12]. However, it is known that an individual’s immuno-
logical response involving the cytokine systems tends to
differ, depending on genetic background as well as on the
type of immunogen [13]. Therefore, just monitoring the
cytokines levels can be misleading without considering the
role of underlying polymorphisms in cytokine genes. Gen-
etic background provides a substrate for intrinsic maldevel-
opment of the brain through environmental influences, by
recruiting neurotrophic factors and cytokines, to trigger
the changes that lead to impaired neural functions. There-
fore, the aim of the present study was to identify the
role of pro-inflammatory and anti-inflammatory cyto-
kine gene polymorphisms in schizophrenia in South
Indian population and to search for epistatic interac-
tions among cytokine genes that may contribute to
schizophrenia risk. Immune response is heavily influ-
enced by environmental, socio-cultural, and ethnic fac-
tors. In order to minimize the role of these modulating
factors, the present study is restricted to Malayalam-
speaking populations from Kerala in South India.
Methods
Subject selection
A case-control association study was carried out using 248
schizophrenia patients (98 males and 146 females) with
mean age group of 33 +/−11 years and 244 controls (83
males and 161 females) with mean age group of 33
+/−7 years that belonged to ethnically matched Malayalam-
speaking population of Kerala, South India. These samples
were genetically [14] and epigenetically [15] stratified based
on their genetic architecture and similar environmental
background as has been reported earlier. Patients were di-
agnosed as per the Diagnostic and Statistical Manual of
Mental Disorders, 4th Edition (DSM-IV) criteria for schizo-
phrenia by two psychiatrists who were a part of the study.
Patients with major affective disorders and schizo-affective
disorder were excluded. Patients with narcotic drugs or
alcohol abuse were also excluded. All the participants who
consented were included in the study. The study was ap-
proved by the Institutional Ethics Committee for Biomed-
ical Subjects, according to the Indian Council of Medical
Research (ICMR) guidelines. Five to ten milliliters of per-
ipheral blood was collected and used for DNA isolation.
Genotyping and functional assessment
Genomic DNA was isolated from lymphocytes using
standard organic extraction method. Twenty-three poly-
morphisms including 22 SNPs and 1 VNTR (variable
number tandem repeat) polymorphism from ten cyto-
kine genes (IL1A, IL1B, IL1RN, IL3, IL4, IL6, IL10, IFNG,
TNFA, and TGFB1) were screened. Genes and SNPs
were selected based on their functional significance and
previous reports on association with any disease condi-
tions. A list of cytokine candidate genes and their selected
polymorphisms indicating the SNP rsID, chromosomal
position, locations, and predicted functional effects are
given in Table 1. Functional effect predictions of SNPs
were done using FuncPred, Functional SNP Prediction
tool (snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm). Func-
tional prediction of the deleterious effect if any of the asso-
ciated SNPs with respect to the functional categories such
as protein coding, splicing regulation, transcriptional regu-
lation, and post-translation was assessed in silico using F-
SNP program (compbio.cs.queensu.ca/F-SNP/), FastSNP
(fastsnp.ibms.sinica. edu.tw), SNPNexus (snpnexus. org),
HaploReg (broadinstitute.org/mammals/haploreg), and
regulomeDB (regulome.stanford.edu). F-SNP extracts
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information from large number of resources such as Poly-
Phen, SIFT, SNPeffect, SNPs3D, LS-SNP, Ensembl, ESE-
finder, RescueESE, ESRSearch, PESX, TFSearch, Consite,
GoldenPath, KinasePhos, OGPET, and Sulfinator to gen-
erate a functional significance (FS) score (Additional file 1:
Table S1).
The genotyping method for each polymorphism is
given in Table 1. Wherever PCR-RFLP and FLP was
carried out, their PCR primers, PCR condition, restric-
tion enzymes, and their allele sizes for each polymorph-
ism are shown in Additional file 1: Table S2. Few SNPs
were genotyped using TaqMan allelic discrimination
assay (Applied Biosystems, Foster City, CA) according
to conditions recommended by the manufacturer in an
Applied Biosystems 7500 or Applied Biosystems 7900HT
Real-Time PCR. The real-time-based KBiosciences
(Hoddesdon, UK) Competitive Allele-Specific PCR geno-
typing system (KASPar) was also used according to manu-
facturer’s instructions for genotyping in an Applied
Biosystems 7500 Real-Time PCR.
Statistical analysis
Allelic, genotypic, haplotypic, and diplotypic frequencies
were calculated and compared using Unphased v3.0.13
software. Association was also analyzed using dominant,
recessive, and additive genetic models. Subgroup analysis
based on gender was also carried out. Deviations from the
Hardy-Weinberg equilibrium (HWE) were tested for all
polymorphisms in controls by comparing observed and
expected genotype frequencies using Haploview v4.1 pro-
gram (www.broad.mit.edu/mpg/haploview). The linkage
disequilibrium (LD) structure among SNPs and haplotype
blocks was visualized by generating LD plots using the
Haploview.
Gene-gene interactions among cytokine genes associ-
ated with schizophrenia were detected by the open-source
multifactor dimensionality reduction (MDR) software
package, version 3.0.1, available at http://www.epista
sis.org/software.html. The Tuned ReliefF (TuRF) filter
algorithm was used to remove noisy SNPs from the
pool of possible candidates. Using this procedure, we
Table 1 List of cytokine candidate genes and their selected polymorphisms
Gene Locus SNP rs id GMAF Alleles Genotyping method Location Predicted functional effect
IL1A 2q13 −889G>A rs1800587 0.2786 G/A TaqMan AD (C_9546481_20)a Promoter TFBS, splicing (ESE or ESS)
IL1B 2q13 +3954 C>T, Phe105Phe rs1143634 0.1328 C/T PCR-RFLP Exon 4 sSNP, splicing (ESE or ESS)
−31T>C rs1143627 0.4724 C/T PCR-RFLP Promoter TFBS
−511C>T rs16944 0.4906 T/C PCR-RFLP Promoter TFBS
IL1RN 2q13 (86)n VNTR rs2234663 1/2 PCR FLP Intron 2 Regulatory protein-binding sites
IL4 5q31.1 −590C>T rs2243250 0.4698 C/T PCR-RFLP Promoter TFBS
−33C>T rs2070874 0.4012 C/T TaqMan AD (C_16176215_10)a Promoter TFBS
IL6 7p21 −597G>A rs1800797 0.1382 G/A PCR-RFLP Promoter TFBS
−572G>C rs1800796 0.3139 G/C PCR-RFLP Promoter TFBS
−174G>C rs1800795 0.1412 G/C PCR-RFLP Promoter TFBS
IL10 1q31 −592A>C rs1800872 0.4349 T/G PCR-RFLP Promoter TFBS
−819C>T rs1800871 0.4347 G/A KASPar assay Promoter TFBS
−1082G>A rs1800896 0.2722 T/C KASPar assay Promoter TFBS
IL3 5q31.1 rs31400T>C rs31400 0.4581 T/C TaqMan AD (C_3141153_10)a Promoter Promoter/regulatory region
rs31480C>T rs31480 0.2883 C/T TaqMan AD (C_2397270_10)a Promoter TFBS
rs40401C>T, Ser27Pro rs40401 0.4195 C/T TaqMan AD (C_2397269_30)a Exon 1 nsSNP, benign
TNFA 6p21.3 −308G>A rs1800629 0.0903 G/A KASPar assay Promoter TFBS
−238G>A rs361525 0.0609 G/A KASPar assay Promoter TFBS
IFNG 12q24.1 +3232A>G rs2069718 0.3832 A/G TaqMan AD (C_15799728_10)a Intron 3 –
+874A>T rs2430561 0.2802 A/T KASPar assay Intron 1 NFKB binding site
TGFB1 19q13.2 +915G>C, Arg25Pro rs1800471 0.0483 G/C KASPar assay Exon 1 nsSNP, benign
+869A>G, Leu10Pro rs1800470 0.4547 A/G TaqMan AD (C_22272997_10)a Exon 1 nsSNP
−509C>T rs1800469 0.368 C/T KASPar assay Promoter TFBS
TFBS transcription factor binding site, ESE exonic splicing enhancer, ESS exonic splicing silencer, sSNP synonymous SNP, nsSNP nonsynonymous SNP, GMAF global
minor allele frequency
aTaqMan allelic discrimination accession numbers
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analyzed the top 4 SNPs in order to understand the
best two-way, three-way, or four-way gene-gene interac-
tions. This reduces the chance of overfitting the data,
which is possible when considering high-order interac-
tions (e.g., >4) in relatively small datasets. The new one-
dimensional multi-locus genotype variable was evaluated
for its ability to classify and predict disease status using
cross-validation and permutation testing. The model with
maximum testing accuracy (TA) and cross-validation
consistency (CVC) was selected as the best model. Statis-
tical significance was evaluated using a 1000-fold permu-
tation test using multifactor dimensionality reduction
permutation testing module (MDRPT v1.0.2 beta) soft-
ware. Finally, we used measures of interaction information
to provide a statistical interpretation of the gene-gene
interaction models. To visualize the nature and strength
of interactions among polymorphisms, an interaction den-
drogram was used. We initially used the whole dataset on
cytokine genes for dendrogram construction. The pres-
ence of LD between SNPs on the same gene may affect
the interaction analysis. Therefore, to reduce the effect
when SNPs were in strong pair-wise LD, defined as r2 >
0.8, one of the pair was randomly dropped. This new
multi-locus attribute now represented the combined effect
of all SNPs in a gene and constructed a refined interaction
dendrogram.
A meta-analysis with the random-effects and fixed-effects
model was performed for previously studied SNPs using
Review Manager 5.2 (reviewmanager.software. informer.
com/5.2/). All the previous studies published in Pubmed
indexed journals which explored similar variants in genes
involved in pro- and anti-inflammatory cytokines were in-
cluded in this study. Family- or sibling-based association
studies, non-interpretable data and articles in non-English
language were excluded from the study. The meta-analysis
included the most studied SNPs in immune response,
IL1Ars1800587 (G-889 A), IL6 rs1800795 (G-174C), and
TNFA rs1800629 (G-308 A) and rs361525 (–238G>A)
(Additional file 1: Table S3). The inconsistency index I2 was
used to assess between-study heterogeneity. A p value of
<0.05 was considered as significant throughout the
analyses.
Results
The association of polymorphisms in pro-inflammatory
and anti-inflammatory cytokine genes with schizophrenia
is presented in Fig. 1. Among cytokine genes, significant
association was observed with pro-inflammatory cytokine
gene polymorphisms of IL1A, IL6, TNFA, and IFNG with
schizophrenia in our study population (Table 2). The
IL1A -889 G>A polymorphism was found to be associ-
ated at both allelic and genotypic level with schizophre-
nia. The allele A of the IL1A -889 polymorphism was
significantly higher in cases (P = 0.026; OR = 1.36; CI =
1.04–1.79). The IL1A -889 genotypes also showed an
association with statistical significance (P = 0.04) with
increased frequency of AA genotype. This genotypic
association enhanced further in a recessive model (AA
vs. GG+GA) with schizophrenia (P = 0.017, OR = 2.08,
CI = 1.12–3.84). In silico prediction indicated altered
transcriptional activity with functional significance
score of 0.21. The allele and genotype frequencies of the
SNPs in IL1B and VNTR in IL1RN did not differ signifi-
cantly between the cases and the controls (Additional file 1:
Table S4). The IL1B -31 and -511 loci in both patient and
control groups were in near complete linkage disequilib-
rium (r2 = 0.98 in controls and r2 = 0.97 in patients).
In IL6, -572 G>C (rs1800796) was found to be associ-
ated with schizophrenia at the genotypic level (P = 0.015)
with an increased frequency of heterozygous genotype.
Fig. 1 Overview of association of cytokine gene polymorphisms with schizophrenia. X-axis shows the polymorphisms screened, and Y-axis shows
the P values for each polymorphism on a logarithmic scale
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In an additive model (GC vs. GG+CC), this association en-
hanced further (P = 0.003, OR = 1.69, CI = 1.18–2.42). IL6
-174G>C (rs1800795) G allele was found to be associated
with schizophrenia (P = 0.037, OR = 1.41, CI = 1.02–1.96).
The GG genotype was observed to be in higher frequency
in patients but in a recessive model (GG vs. GC+CC), this
association with schizophrenia turned significant (P = 0.034,
OR = 1.51, CI = 1.03–2.21). Diplotype analysis showed that
the combination of IL6 -572 GC and the major genotype of
IL6 -174 GG genotypes were strongly associated (P = 0.001,
OR = 1.5). In silico prediction indicated altered tran-
scriptional activity for IL6 -572 G>C (rs1800796) and
IL6 -174G>C (rs1800795) with functional significance
score of 0.21 and 0.39, respectively.
In TNFA, -238G>A (rs361525) polymorphism was
found to be significantly associated at the genotypic
and allelic levels with schizophrenia. The allele A was
significantly higher in cases when compared to controls
(P = 0.021, OR = 1.74, CI = 1.08–2.82). The genotype
distribution in patients and controls differed significantly
(P = 0.019) with higher frequency of heterozygous geno-
type in patients. This association was observed significant
(P = 0.01, OR = 1.93) in dominant model (AA+AG vs. GG)
but enhanced further in an additive model (GA vs. GG
+AA) (P = 0.0059 OR = 2.05, CI = 1.22–3.45). In silico
prediction indicated altered transcriptional activity for
this SNP with a functional significance score of 0.21.
TNFA -308 G>A polymorphism was not found to be as-
sociated with schizophrenia at allele and genotype level.
But at haplotypic level, the presence of TNFA -308 G
allele along with TNFA -238 A allele was significantly
associated (P = 0.02, OR = 1.75) with schizophrenia. Sig-
nificant diplotypic association was also observed with
the presence of -308 GG genotype along with -238 GA
genotype (P = 0.01, OR = 2.05).
IFNG rs2069718 was found to be associated with
schizophrenia in our population at the genotypic level
with increased frequency of AA genotype in schizo-
phrenia patients (P = 0.026). This association enhanced
further in a recessive model (AA vs. AG+GG)-based
Table 2 Genotype and allele frequencies of the associated pro-inflammatory cytokine genes and their functional significance score
Polymorphism Genotype Patients Controls P value Model-based P value/OR (CI) Allele Patients Controls P value/OR (CI) FS score
IL1A -889G>A GG 102 (0.42) 118 (0.49) G 313 (0.64) 344 (0.71)
rs1800587 GA 109 (0.45) 108 (0.44) 0.04 0.017a A 175 (0.36) 142 (0.29) 0.026 0.21
AA 33 (0.14) 17 (0.07) a2.1 (1.08–4) 1.36 (1.04–1.8)
IL6 -597G>A GG 165 (0.67) 149 (0.61) G 402 (0.82) 382 (0.78)
rs1800797 GA 72 (0.29) 84 (0.34) 0.38 A 90 (0.18) 106 (0.22) 0.18
AA 9 (0.04) 11 (0.05)
IL6 -572G>C GG 62 (0.25) 81 (0.33) G 268 (0.54) 273 (0.56)
rs1800796 GC 144 (0.59) 111 (0.45) 0.015 0.003b C 224 (0.46) 215 (0.44) 0.64
CC 40 (0.16) 52 (0.21) b1.7 (1.18–2.42)
IL6 -174G>C GG 177 (0.72) 153 (0.63) G 415 (0.84) 385 (0.79)
rs1800795 GC 61 (0.25) 79 (0.33) 0.10 0.034c C 77 (0.16) 101 (0.21) 0.04 0.40
CC 8 (0.03) 11 (0.05) c1.5 (1.03–2.2) 1.4 (1.02–1.96)
TNFA -308G>A GG 202 (0.82) 192 (0.78) G 443 (0.9) 435 (0.89)
rs1800629 GA 39 (0.16) 51 (0.21) 0.09 A 49 (0.1) 53 (0.11) 0.64
AA 5 (0.02) 1 (0.01)
TNFA -238G>A GG 199 (0.80) 216 (0.89) G 445 (0.9) 457 (0.94)
rs361525 GA 47 (0.19) 25 (0.1) 0.019 0.006d A 49 (0.1) 29 (0.06) 0.02 0.21
AA 1 (0.01) 2 (0.01) d2.05 (1.2–3.45) 1.74 (1.08–2.8)
IFNG +3232A>G AA 85 (0.35) 61 (0.25) A 285 (0.58) 265 (0.55)
rs2069718 AG 115 (0.47) 143 (0.59) 0.026 0.009f, f1.6 (1.1–2.29) G 203 (0.42) 221 (0.45) 0.22 ND
GG 44 (0.18) 39 (0.16) 0.019e, e1.6 (1.08–2.36)
IFNG +874A>T AA 96 (0.39) 107 (0.44) A 300 (0.61) 316 (0.65)
rs2430561 AT 108 (0.44) 102 (0.42) 0.40 0.40 T 192 (0.39) 168 (0.35) 0.16
TT 42 (0.17) 33 (0.14)
FS score functional significance score
aRecessive model (AA vs. GG+GA); bAdditive model (GC vs. GG+CC); cRecessive model (GG vs. GC+CC); dAdditive model (GA vs. GG+AA); eRecessive model (AA vs.
AG+GG); fAdditive model (AG vs. AA+GG)
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association (P = 0.019, OR = 1.59, CI 1.08–2.36), while
the heterozygous AG genotype had a significant protective
effect (P = 0.009, OR = 1.60, CI 1.12–2.29). Using sub-
group analysis based on gender, we observe a significantly
strong association with IFNG rs2069718 (P < 0.001) with
AA as risk genotype for females.
The anti-inflammatory cytokine genes IL4, IL10 and
TGFB1, and IL3 were not found to be associated with
schizophrenia in our South Indian Kerala Population. The
observed allele and genotype frequencies for these cyto-
kine gene SNPs are given in Additional file 1: Table S4. In
silico prediction of transcriptional activity of the studied
SNPs with their functional significance score is mentioned
in Additional file 1: Table S1. Interestingly, the associated
SNPs were found to have higher functional significance
for altered transcriptional activity.
Gene-gene interactions—MDR analysis
The four best SNPs selected by the TuRF filter algorithm
were IL6 -572G>C, IL6 -174G>C, IFNG rs2430561, and
IFNG rs2069718. An exhaustive MDR analysis that evalu-
ated all possible combinations of these four polymor-
phisms was carried out. Table 3 summarizes the gene-gene
interactions among cytokine gene polymorphisms pre-
dicted using MDR and shows the best model on each
order. The IL6 -572G>C turns out to be the best single-
locus model, and it can be seen having significant epistatic
interactions with IFNG SNPs (P = 0.0095) with testing ac-
curacy of 0.5837, CVC of 10/10. Figure 2 summarizes the
distribution of cases and controls for the three-locus geno-
type combinations of IL6-572, IFNG rs2430561, and IFNG
rs2069718 associated with high and low risk for schizo-
phrenia. The pattern of high-risk and low-risk cells differs
across each of the multi-locus dimensions. Such differ-
ences are evidence of a gene-gene interaction. The three
SNPs in the three-factor model, which formed the overall
best model in our analysis, i.e., IL6 -572, IFNG rs2430561,
and IFNG rs2069718, were combined using the attribute
construction function to create a new single multi-locus
attribute (IL6-572_IFNGrs2430561_ IFNGrs2069718) to
the dataset. Next, we did a forced analysis with that single
constructed attribute and the statistics for the analysis of
that variable was obtained. Interestingly, this new single
multi-locus attribute had a high testing accuracy of 0.6182
along with 10/10 cross-validation consistency and a very
significant permutation P value <0.001. This can further
be visualized by tree diagram indicating that the pro-
inflammatory cytokine genes were clustered on the same
branch and their proximity in the tree diagram clearly in-
dicates that these genes may interact together to modulate
the risk of schizophrenia (Fig. 3).
Meta-analysis
We performed a meta-analysis for all the SNPs in the
present study with the previous reports for the same SNPs
in different ethnicities. For IL1A rs1800587, an overall sig-
nificant association (P = 0.01) was observed in the fixed-
effects model (Fig. 4). However, higher heterogeneity (67 %)
was observed between the studies. To reduce the hetero-
geneity, a possible method is to restrict the analysis to the
studies done in the Asian populations. The overall effect
significantly increased (P = 0.003), but the heterogeneity
remains unaltered. Similarly, we performed meta-analysis
with IL6 rs1800795 (-174G>C) while no sufficient data
was available for IL6 rs1800796 (-572G>C). Overall effect
was found to be negative with no association but was indi-
cative of high heterogeneity among the study population
(I2 = 77 %) (Additional file 2: Figure S1). Majority of data
on IL6 polymorphisms come from European population.
Interestingly, IL6 rs1800795 (-174G>C) and rs1800796
(-572G>C) were strongly associated in our south Indian
population alone. Meta-analysis with TNFA rs1800629
(-308 G>A) and rs361525 (-238G>A) was carried out with
none of the SNPs showing any significant overall effect
(Additional file 3: Figure S2, Additional file 4: Figure S3).
Both these SNPs indicated high heterogeneity among
study population. Extensive studies have been carried out
with TNFA rs1800629 (-308 G>A) while studies with
rs361525 (-238G>A) is just emerging. Our positive associ-
ation with rs361525 (-238G>A) might indicate significance
of this SNP to be replicated in larger ethnic population.
Discussion
In the present study, we report significant association of
SNPs in pro-inflammatory cytokine genes IL1A, IL6,TNFA,
and IFNG with schizophrenia in the Malayalam-speaking
Dravidian population of India. Contrary to findings from
other populations, we did not observe association of poly-
morphisms in anti-inflammatory cytokine genes with
schizophrenia, in our study population. Equilibrium be-
tween pro- and anti-inflammatory cytokine is essential to
maintain the homeostasis in the system. Pro-inflammatory
cytokines such as IL-1α, IL-6, TNF-α, and IFN- γ are re-
sponsible for early responses and amplify inflammatory
reactions, whereas anti-inflammatory cytokines, which in-
clude IL-4, IL-10, and TGF-β, have the opposite effect, in
that they limit the inflammatory responses. The association
of pro-inflammatory cytokine genes with schizophrenia in
Table 3 Gene-gene interactions predicted using MDR
Best combination in each order TA CVC P value
IL6-572 0.562 10/10 0.100
IFNGrs2430561, IFNGrs2069718 0.5783 10/10 0.018
IL6-572, IFNGrs2430561, IFNGrs2069718a 0.5837 10/10 0.0095
IL6-572, IL6-174, IFNGrs2430561, IFNGrs2069718 0.5739 10/10 0.0305
TA testing accuracy, CVC cross-validation consistency
aBest model
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our population validates the hypothesis of excess of
pro-inflammatory cytokine in the pathophysiology of
schizophrenia. This could relate to the elevated levels of
pro-inflammatory cytokines in patients with schizophrenia.
IL-1α is a pro-inflammatory cytokine, and we observe a
strong association with IL1A -889 SNP. The IL1A-889
SNP is in the promoter region which has a predicted tran-
scription factor binding site. We found an association of
IL1A -889 A allele and AA genotype with schizophrenia in
our population. IL1A -889 allele A is reported to be asso-
ciated with a fourfold increase of IL-1α production [16],
and the GG genotype is associated with lower transcrip-
tional activity and lower levels of circulating IL-1α, in
comparison to AA genotype [17]. IL1 has been described
as an astroglial growth factor that has a role in brain de-
velopment [18]. It can also modify the metabolism of neu-
rotransmitters or influence neural development [19].
Thus, the association of IL1A high producer genotype AA
and allele A with schizophrenia may imply alterations in
the early developmental process of brain or neural devel-
opment or modify the metabolism of neurotransmitters.
In meta-analysis, IL1A rs1800587 was found to be signifi-
cantly associated from global perspective (P = 0.01), which
enhanced further when the association was evaluated
from the Asian population perspective (P = 0.003). How-
ever, higher heterogeneity among the study population
was observed. An association with the A allele was ob-
served in two study population, i.e., Singapore and Kerala
(present study), in India. Interestingly, both these places
lie below the tropic of cancer near to the equator as
compared to the rest of the study populations that lie
above the tropic of cancer. This might indicate how en-
vironment shapes our cytokine gene selection process.
A comparison of the allelic frequencies of the SNP
among the various world populations also suggests a
similar pattern.
Fig. 2 Distribution of cases and controls for the three-locus genotype combinations of IL6 -572, IFNG rs2430561, and IFNG rs2069718 associated
with high risk and low risk for schizophrenia using MDR analysis (left bar in cell indicates cases and right bar indicates controls)
Fig. 3 MDR interaction dendrogram showing interactions of pro-and anti-inflammatory cytokine genes
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With IL-6, a multifunctional cytokine with pro-
inflammatory, immunoregulatory, and neuroprotective
activities, we report a strong association of IL6-174 G
allele and GG genotype and IL6-572 GC genotype with
schizophrenia in South Indian population. The change
from a G to C at position 174 creates a potential binding
site for the transcription factor neurofibromatosis type I
(NF-1), which comprises a family of structurally related
transcription factors active in many cell types [20]. The G
allele of IL6-174 SNP was reported to be associated with
higher expression levels [20]. Both individuals homozy-
gous or heterozygous for the G allele have been shown to
have higher IL-6 levels in the plasma, higher IL6 gene
transcriptional activity, and higher inducible IL-6 re-
sponses, when compared to subjects homozygous for the
C allele [20, 21]. In our population, we found an associ-
ation of the high producer allele G and GG genotype of
this SNP with schizophrenia. Thus, overexpression of pro-
inflammatory cytokine IL-6 may be a factor for schizo-
phrenia development in our population. A study in the
Polish population suggests that the IL6 -174G>C is associ-
ated with the risk of paranoid schizophrenia [22], while a
Chinese study revealed no association of the SNP with
schizophrenia [23]. In Armenian population, an associ-
ation of rs1800795 (-174G/C) with schizophrenia and cor-
responding blood level of IL-6 in patients was found to be
1.5-fold higher than in controls [24]. Meta-analysis with
IL6 rs1800795 (-174G>C) was indicative of having no ef-
fect from global perspective and was also suggestive of
high heterogeneity among study populations. Interestingly,
we report association with the high producer G allele
which is in contrast to the associated allele in European
population. Meta-analysis could not be carried out for IL6
rs1800796 (-572G>C) due to lack of sufficient data. How-
ever, genome-wide linkage analysis has identified the
chromosome 7p21.1–22.3 region, which contains the IL6
gene, as one of the susceptibility loci to schizophrenia
[25]. IL-6 is not only synthesized and released in immune
cells of the peripheral blood; it is also produced by acti-
vated astrocytes and microglia cells in the central nervous
system (CNS). In the CNS, IL-6 has been found to regu-
late brain development, synaptic plasticity, and various
behaviors related to feeding, sleep, and stress [26]. A
strong relationship between IL-6 and neurotransmitter
production has been reported by various studies. IL-6 can
stimulate neurons in vitro to secrete dopamine [27]. The
peripheral application of IL-6 in animal experiments en-
hanced the dopaminergic and serotonergic turnover in the
hippocampus and frontal cortex, without affecting nor-
adrenaline [28]. These observations point towards direct
influence of IL-6, on the catecholaminergic neurotrans-
mitter system which might be mediated by environmental
effects on the high producer allele.
Tumor necrosis factor-alpha (TNF-α) is a pro-in-
flammatory cytokine, which is secreted in the CNS by neu-
rons, glial cells, and astrocytes [29]. We found a significant
association of TNFA -238G>A (rs361525) polymorphism
with higher prevalence of allele A and heterozygous geno-
type GA with schizophrenia. TNFA -238G>A located in the
promoter region has a potential transcription binding site.
Fig. 4 Meta-analysis of IL1A rs1800587 risk allele A versus G allele in schizophrenia patients in comparison to normal control using fixed and
random model
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Earlier studies with TNFA polymorphisms have reported
contradictory observation with schizophrenia in various
ethnic populations, while few studies have reported positive
associations [30–32] and equal number of studies have
failed to replicate these positive associations of TNFA poly-
morphisms in schizophrenia [33–35]. These discrepancies
indicate the role of ethnic variation as majority of the
positive associations were reported in Caucasian popu-
lations while lack of association was observed
predominantly in populations of East Asian origin.
Meta-analysis with TNFA rs1800629 (-308 G>A) and
rs361525 (-238G>A) indicate lack of any significant im-
pact of these SNPs to have a global effect. Extensive
heterogeneity among study population might indicate
ethnicity-specific impact in influencing their role in the
disease. Studies with rs361525 (-238G>A) is just emer-
ging and our positive association with this SNP might
indicate significance of this SNP to be replicated in larger
ethnic population. The positive association in the present
study could be of significance as TNF-α has been demon-
strated to have cytotoxic effects on embryonic mesen-
cephalic dopaminergic neurons [36], which are suggested
to have an important role in the etiopathogenesis of
schizophrenia. The various effects of TNF-α suggest that
disturbances in its levels may affect the functioning of the
brain. TNF-α has been shown to have a stimulatory effect
on the catecholaminergic system, whereas chronic TNF-α
release induces an inhibitory effect [37]. This is in line
with the theory that acute schizophrenia involves a hyper-
dopaminergic state with positive psychotic symptoms,
whereas chronic schizophrenia with predominantly
negative symptoms is associated with a relative hypodo-
paminergic state [38]. TNFA gene is located within the
major histocompatibility complex (MHC) region at the
short arm of chromosome 6 (6p21.3), which is impli-
cated in linkage [39] and genome-wide association studies
(GWAS) studies [40–42] in genetic susceptibility to schizo-
phrenia. Thus, the TNFA gene can be considered a pos-
itional as well as a functional candidate gene in the search
for genetic factors contributing to the development of
schizophrenia.
IFN-γ is a pro-inflammatory cytokine, which is import-
ant for regulating immune and inflammatory events. IFN-
γ is known to upregulate both class I and II MHC antigen
expression on a variety of cells. IFN-γ can enhance the
function of microglia by increasing the production of some
cytokines, e.g., TNF-α, nitric oxide, and of free radicals
[43], and thus play an important role in the induction of
various central nervous system pathologies. Therefore, as-
sociation of IFNG rs2069718 AA genotype with schizo-
phrenia might be of significance. Earlier reports have
shown a gender-specific association of IFNG +874A>T
(rs2430561) polymorphism with paranoid schizophrenia in
males, but not in females [44]. Reduced IFN-γ production
has been reported to be associated with acute exacerbation
of schizophrenia [45]. Elevated levels of IFN-γ were re-
ported to be associated with positive symptoms of para-
noid schizophrenia while the negative symptoms were
associated with downregulated IFN-γ [46]. IFN-γ also in-
hibits serotonin release [47]. These evidences strongly in-
dicate that IFNG rs2069718 may play a role in immune
changes occurring in schizophrenia.
Collectively, these genetic associations with multiple
pro-inflammatory cytokines, by interacting with environ-
mental insults, may result in slow and progressive damage
to brain, precipitating in schizophrenia. In our gene-gene
interaction analysis, IL6 and IFNG were found to have
strong epistatic interaction. The proximity of clustering of
pro-inflammatory cytokine genes indicates that these
genes interact together to modulate the risk of schizophre-
nia. In fact, this interaction between the pro-inflammatory
cytokine genes may reflect the production of cytokines at
molecular and cellular level too. IL-6 is secreted by a wide
range of cells including fibroblasts, monocytes, B cells,
endothelial cells, T cells, microglia, and astrocytes. De-
pending upon the cell type, synthesis of IL6 is known to
be induced by a variety of agents including other pro-
inflammatory cytokines IL-1, TNF-α, and IFN-γ [48]. Ob-
servations on genetic association in the present study also
indicate that pro-inflammatory cytokines are more likely
to be amplified through molecular heterotic effect of IL6
and TNFA towards the risk of developing schizophrenia in
South Indian population. Molecular heterosis is becoming
increasingly evident in complex disorders [49] which can
impact at both transcriptional and translational level [50].
Therefore, it is important to identify the nature of inflam-
matory response that is amplified by the environment, and
accordingly, may indicate whether the shift will be towards
Th1 response or Th2 response. Complementary lines of
evidence imply that dysregulation of pro-inflammatory cy-
tokines plays a key role in schizophrenia through various
psycho-social and environmental stressors. Prenatal ex-
posure to a number of adverse factors—such as maternal
infection and diabetes—is known to result in elevated
levels of maternal pro-inflammatory cytokines which can
mediate adverse effects on fetal brain development [51].
The pro-inflammatory mediators favor the production of
quinolinic acid and are also known to impair the ability of
astrocytes to remove glutamate [52]. Therefore, glutamate
and quinolinic acid through their excitatory activity may
induce neurotoxic effects through NMDA receptor agon-
ism. Interestingly, the antipsychotics are also known to in-
hibit the release of pro-inflammatory cytokines [53].
Therefore, one would presume that the therapeutic re-
sponse in schizophrenia in South Indian patients may be
contributed through immune regulatory pathway. Cyto-
kine expression and modulation are heavily influenced by
environmental factors. The present study indicates that
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the high-producer alleles of pro-inflammatory cytokines
are key to the development of schizophrenia in South
India. Interaction of environmental stressors with these
high-producer alleles of pro-inflammatory cytokines may
suggest that even a lower threshold of these stressors may
be sufficient to induce an effect that may result in schizo-
phrenia. However, none of the associated SNPs remain
significant after correction for multiple testing; therefore,
they should be considered suggestive of their role in
schizophrenia. The limitation of the study is with large ef-
fect size, and this would involve increased sample size.
Large effect sizes are uncommon in complex diseases;
therefore, multiple testing in schizophrenia and all the
more for immune response genes may not hold promise.
Increasing sample size would mean sampling genetically
non-stratified sample or phenotypically divergent samples
which will further compromise the observation. This is
also the reason why genetic studies are not replicable
across ethnicities, and this conflict is also evident in the
meta-analysis which indicates high heterogeneity.
Conclusions
It is important to identify the nature of inflammatory re-
sponse amplified by the environment, whether the shift
will be towards Th1 response or Th2 response. The
present study provides evidence of strong independent as-
sociations of pro-inflammatory cytokine genes IL1A, IL6,
TNFA, and IFNG with schizophrenia and their interac-
tions in Dravidian South Indian population. The associ-
ated functional variants in the study are involved with
increased expression resulting in higher production of the
pro-inflammatory cytokines IL-1α, IL-6, TNF-α, and IFN-
γ. The interaction of immunological stressors with these
high-producer alleles of pro-inflammatory cytokines may
suggest that even a lower threshold may be sufficient to
induce a resultant chronic effect on psycho-social and en-
vironmental stressors that may result in the development
of schizophrenia. These pro-inflammatory mediators
are likely to induce excitatory activity through the pro-
duction of quinolinic acid and impair the ability to re-
move glutamate resulting in neurotoxic effects. These
findings support the hypothesis that genetically deter-
mined changes in cytokine regulation may contribute
to the pathogenesis of schizophrenia. Understanding
environmental factors that influence the expression of
these pro-inflammatory cytokine genes or their inter-
action can possibly help us in dissecting the resultant
phenotypic variation in schizophrenia. Interestingly, the
antipsychotics are also known to inhibit the release of
pro-inflammatory cytokines. Therefore, one would pre-
sume that the therapeutic response in schizophrenia in
South Indian patients may be contributed through im-
mune regulatory pathway.
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